Open an account

ADMA Biologics

ADMA · NASDAQ

$11.23+$0.16 (+1.45%)TodayMarket closed ·
Prev close $11.07

About ADMA

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

Employees
647
Headquarters
Ramsey, New Jersey
Listed
Oct 17, 2013
Sector
Health Care
Industry
Biotechnology
Website
admabiologics.com

ADMA key statistics

Market cap
2.52B
Price-earnings ratio
15.81
Dividend yield
—
Average volume
2.98M
Volume
2.90M
Open price
$11.12
High today
$11.33
Low today
$11.03
52 Week high
$20.46
52 Week low
$7.21

ADMA Biologics (ADMA) at a glance

ADMA Biologics (ADMA) last traded at $11.23, with a market cap of 2.52B and a price-to-earnings ratio of 15.81.

Today the stock has traded between $11.03 and $11.33. The current price is 1.8% above the day's low and 0.8% below its high.

Volume so far is 2.90M shares, in line with the average of 2.98M shares a day.

Over the past year ADMA Biologics has ranged from $7.21 to $20.46, and now sits 30% of the way up that range.

ADMA Biologics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported $0.16 per share against an estimate of $0.176.

ADMA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 9.6% on average.

  1. Q3 FY24: reported $0.15 per share against an estimate of $0.1326
  2. Q4 FY24: reported $0.14 per share against an estimate of $0.153
  3. Q1 FY25: reported $0.11 per share against an estimate of $0.1598
  4. Q2 FY25: reported $0.14 per share against an estimate of $0.1428
  5. Q3 FY25: reported $0.15 per share against an estimate of $0.153
  6. Q4 FY25: reported $0.20 per share against an estimate of $0.1887
  7. Q1 FY26: reported $0.19 per share against an estimate of $0.204
  8. Q2 FY26: reported $0.16 per share against an estimate of $0.176

ADMA news

  • Press releasePRNewswire

    Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

  • Press releasePRNewswire

    Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

  • Press releasePRNewswire

    ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

  • Press releasePRNewswire

    ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law

  • Press releasePRNewswire

    Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

  • Press releasePRNewswire

    ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

  • Press releaseBusiness Wire

    CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

  • Press releasePRNewswire

    ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

Similar companies

Companies in the same industry as ADMA Biologics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.